{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:43:15Z","timestamp":1793515395975,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013700","name":"National Comprehensive Cancer Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ygyno.2023.08.020","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T01:04:55Z","timestamp":1694567095000},"page":"165-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue"],"prefix":"10.1016","volume":"177","author":[{"given":"Alexi A.","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Poort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tavormina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Schmiege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana M.","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T.","family":"Slivjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Salinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley F.","family":"Haggerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna J.","family":"Arch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.08.020_bb0005","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/PPO.0000000000000558","article-title":"Poly(ADP-ribose) polymerase inhibitor inhibition in ovarian cancer: a comprehensive review","volume":"27","author":"Moore","year":"2021","journal-title":"Cancer J."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial","volume":"41","author":"DiSilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0015","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic Cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0025","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with Olaparib in metastatic castration-resistant prostate Cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1200\/JCO.22.00405","article-title":"A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with Rucaparib following chemotherapy for metastatic urothelial carcinoma","volume":"41","author":"Crabb","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0035","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2019.06.012","article-title":"Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: a meta-analysis of randomized controlled trials","volume":"141","author":"Ruiz-Schutz","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0045","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ygyno.2020.10.034","article-title":"Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: a qualitative study","volume":"160","author":"Poort","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0050","first-page":"CD012030","article-title":"Psychosocial interventions for fatigue during cancer treatment with palliative intent","volume":"7","author":"Poort","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0055","series-title":"Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change","author":"Hayes","year":"1999"},{"key":"10.1016\/j.ygyno.2023.08.020_bb0060","series-title":"Acceptance and Commitment Therapy: The Process and Practice of Mindful Change","author":"Hayes","year":"2012"},{"key":"10.1016\/j.ygyno.2023.08.020_bb0065","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1023\/A:1008900413113","article-title":"Measurement of fatigue in cancer patients: further validation of the fatigue symptom inventory","volume":"9","author":"Hann","year":"2000","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0070","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1008842517972","article-title":"Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory","volume":"7","author":"Hann","year":"1998","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0075","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jpainsymman.2007.11.013","article-title":"Identifying clinically meaningful fatigue with the fatigue symptom inventory","volume":"36","author":"Donovan","year":"2008","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0080","doi-asserted-by":"crossref","first-page":"E28","DOI":"10.1097\/NCC.0000000000000446","article-title":"Adapting an evidence-based intervention to address targeted therapy-related fatigue in chronic myeloid leukemia patients","volume":"41","author":"Poort","year":"2018","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0085","series-title":"Acceptance and Commitment Therapy: An Experiential Approach to Behavior Change","author":"Hayes","year":"1999"},{"key":"10.1016\/j.ygyno.2023.08.020_bb0090","series-title":"Acceptance and Commitment Therapy: The Process and Practice of Mindful Change","author":"Hayes","year":"2012"},{"key":"10.1016\/j.ygyno.2023.08.020_bb0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/0011000012461955","article-title":"Quality of life in advanced cancer: an acceptance and commitment therapy view","volume":"41","author":"Angiola","year":"2013","journal-title":"Couns. Psychol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12904-022-01087-z","article-title":"A randomized controlled trial of a multi-modal palliative care intervention to promote advance care planning and psychological well-being among adults with advanced cancer: study protocol","volume":"21","author":"Arch","year":"2022","journal-title":"BMC Palliat. Care."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ygyno.2020.10.034","article-title":"Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: a qualitative study","volume":"160","author":"Poort","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0110","series-title":"Mastery of your Anxiety and Panic: Therapist Guide","author":"Craske","year":"2007"},{"key":"10.1016\/j.ygyno.2023.08.020_bb0115","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1037\/0022-006X.72.6.1050","article-title":"A randomized trial of methods to help clinicians learn motivational interviewing","volume":"72","author":"Miller","year":"2004","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0120","first-page":"1","article-title":"Training therapists in evidence-based practice: a critical review of studies from a systems-contextual perspective","volume":"17","author":"Beidas","year":"2010","journal-title":"Clin Psychol (New York)."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0125","unstructured":"Facing Forward: Life aAfter Cancer Treatment. https:\/\/www.cancer.gov\/publications\/patient-education\/facing-forward: National Cancer Institute, 2018."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jclinepi.2019.02.011","article-title":"The selection of comparators for randomized controlled trials of health-related behavioral interventions: recommendations of an NIH expert panel","volume":"110","author":"Freedland","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0135","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PSY.0b013e318218e1fb","article-title":"Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions","volume":"73","author":"Freedland","year":"2011","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/PSY.0b013e3182765dd2","article-title":"Can attention control conditions have detrimental effects on behavioral medicine randomized trials?","volume":"75","author":"Pagoto","year":"2013","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0145","first-page":"169","article-title":"The fatigue symptom inventory: a systematic review of its psychometric properties","volume":"19","author":"Donovan","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ygyno.2023.08.020_bb0150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s41687-022-00488-1","article-title":"Comparative responsiveness and minimally important difference of fatigue symptom inventory (FSI) scales and the FSI-3 in trials with cancer survivors","volume":"6","author":"Mosher","year":"2022","journal-title":"J Patient Rep Outc."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0155","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0160","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0165","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12888-016-0728-6","article-title":"Assessment of depression severity with the PHQ-9 in cancer patients and in the general population","volume":"16","author":"Hinz","year":"2016","journal-title":"BMC Psychiatry."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0170","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0175","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11136-015-1088-2","article-title":"Empirical validation of the English version of the fear of Cancer recurrence inventory","volume":"25","author":"Lebel","year":"2016","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0180","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2001.19.6.1809","article-title":"Reliability and validity of the functional assessment of cancer therapy-ovarian","volume":"19","author":"Basen-Engquist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jad.2020.01.032","article-title":"Sensitivity to change and minimal clinically important difference of the 7-item generalized anxiety disorder questionnaire (GAD-7)","volume":"265","author":"Toussaint","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0190","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/PSY.0000000000000322","article-title":"Patient health questionnaire anxiety and depression scale: initial validation in three clinical trials","volume":"78","author":"Kroenke","year":"2016","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of Cancer therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1037\/ccp0000630","article-title":"Randomized trial of acceptance and commitment therapy for anxious cancer survivors in community clinics: outcomes and moderators","volume":"89","author":"Arch","year":"2021","journal-title":"J. Consult. Clin. Psychol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2023.08.020_bb0205","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.12-S1-4","article-title":"Cancer-related fatigue: the scale of the problem","volume":"12","author":"Hofman","year":"2007","journal-title":"Oncologist."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0210","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaoncol.2016.6914","article-title":"Comparison of pharmaceutical, psychological, and exercise treatments for Cancer-related fatigue: a Meta-analysis","volume":"3","author":"Mustian","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2023.08.020_bb0215","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1200\/JCO.20.01924","article-title":"PARP inhibitors in the Management of Ovarian Cancer: ASCO guideline","volume":"38","author":"Tew","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825823014622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:06:31Z","timestamp":1758773191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825823014622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":43,"alternative-id":["S0090825823014622"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.08.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot randomized trial of an acceptance-based telehealth intervention for women with ovarian cancer and PARP inhibitor-related fatigue","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}